{"&cites=7438817963127421284&as_sdt=2005&sciodt=0,5&hl=en":[{"title":"PD-1 blockade in tumors with mismatch-repair deficiency","url":"https://www.nejm.org/doi/full/10.1056/nejmoa1500596","authors":["DT Le","DT Le JN Uram","DT Le JN Uram H Wang","DT Le JN Uram H Wang BR Bartlett…"],"year":2015,"numCitations":4854,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa1500596","citationUrl":"http://scholar.google.com/scholar?cites=10258601064941698851&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:Iz9L8FDfXY4J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=10258601064941698851&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc","p":1,"exp":1596879364698},{"title":"Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer","url":"https://science.sciencemag.org/content/348/6230/124.abstract","authors":["NA Rizvi","NA Rizvi MD Hellmann","NA Rizvi MD Hellmann A Snyder","NA Rizvi MD Hellmann A Snyder P Kvistborg…"],"year":2015,"numCitations":4359,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4993154/","citationUrl":"http://scholar.google.com/scholar?cites=6616874989748115658&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:ylga177c01sJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=6616874989748115658&hl=en&as_sdt=2005&sciodt=0,5","publication":"science.sciencemag.org"},{"title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","url":"https://www.nature.com/articles/nature14011?page=1","authors":["RS Herbst","RS Herbst JC Soria","RS Herbst JC Soria M Kowanetz","RS Herbst JC Soria M Kowanetz GD Fine","RS Herbst JC Soria M Kowanetz GD Fine O Hamid…"],"year":2014,"numCitations":3082,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4836193/","citationUrl":"http://scholar.google.com/scholar?cites=16172811975131816039&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:Z2Dq3M1eceAJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16172811975131816039&hl=en&as_sdt=2005&sciodt=0,5","publication":"nature.com"},{"title":"The future of immune checkpoint therapy","url":"https://science.sciencemag.org/content/348/6230/56.abstract","authors":["P Sharma","P Sharma JP Allison"],"year":2015,"numCitations":2228,"citationUrl":"http://scholar.google.com/scholar?cites=1385363128569161210&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:-uVJ62zMORMJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1385363128569161210&hl=en&as_sdt=2005&sciodt=0,5","publication":"science.sciencemag.org"},{"title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","url":"https://www.sciencedirect.com/science/article/pii/S014067361632517X","authors":["A Rittmeyer","A Rittmeyer F Barlesi","A Rittmeyer F Barlesi D Waterkamp","A Rittmeyer F Barlesi D Waterkamp K Park…"],"year":2017,"numCitations":2073,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6886121/","citationUrl":"http://scholar.google.com/scholar?cites=8337560628463052007&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:56TSoDf3tHMJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=8337560628463052007&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a …","url":"https://www.sciencedirect.com/science/article/pii/S0140673616005614","authors":["JE Rosenberg","JE Rosenberg J Hoffman"],"year":2016,"numCitations":2031,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480242/","citationUrl":"http://scholar.google.com/scholar?cites=5432023266656526845&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:_SG4hGFsYksJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=5432023266656526845&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","url":"https://www.sciencedirect.com/science/article/pii/S1535610815000896","authors":["SL Topalian","SL Topalian CG Drake","SL Topalian CG Drake DM Pardoll"],"year":2015,"numCitations":1983,"pdf":"https://www.sciencedirect.com/science/article/pii/S1535610815000896","citationUrl":"http://scholar.google.com/scholar?cites=762198590603665813&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:lSE8cZTfkwoJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=762198590603665813&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled …","url":"https://www.sciencedirect.com/science/article/pii/S0140673616005870","authors":["L Fehrenbacher","L Fehrenbacher A Spira","L Fehrenbacher A Spira M Ballinger","L Fehrenbacher A Spira M Ballinger M Kowanetz…"],"year":2016,"numCitations":1585,"pdf":"http://cloudfront.practiceupdate.net/zone/els.pracuponcology_nsclc/NSCLC-2_Fehrenbacher_Poplar.pdf","citationUrl":"http://scholar.google.com/scholar?cites=16891754268056670910&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:vtK0rAKRa-oJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16891754268056670910&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","url":"https://www.sciencedirect.com/science/article/pii/S0092867415003177","authors":["P Sharma","P Sharma JP Allison"],"year":2015,"numCitations":1237,"pdf":"https://www.sciencedirect.com/science/article/pii/S0092867415003177","citationUrl":"http://scholar.google.com/scholar?cites=10192697398975213842&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:EjH3-Ee8c40J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=10192697398975213842&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Elements of cancer immunity and the cancer–immune set point","url":"https://www.nature.com/articles/nature21349","authors":["DS Chen","DS Chen I Mellman"],"year":2017,"numCitations":1258,"citationUrl":"http://scholar.google.com/scholar?cites=5331709024697737438&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:3mDa_hsJ_kkJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=5331709024697737438&hl=en&as_sdt=2005&sciodt=0,5","publication":"nature.com"}]}